Pimasertib (AS-703026)作用于MM细胞系，是一种高度选择性的，有效的，ATP非竞争性的，MEK1/2变构抑制剂，IC50为0.005-2 μM。AS703026是新型选择性的MEK1/2抑制剂，结合到特定MEK变构位点，具有强激酶选择性。AS703026抑制人类多发性骨髓瘤细胞(包括U266和INA-6细胞)生长和存活,IC50分别为5和11 nM。细胞周期停在G0-G1期可调节AS703026的抑制效果，且伴随着MAF致癌基因表达的降低。

≥98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

MSC1936369B；Pimasertib

DMSO ：80 mg/mL (185.5 mM)

MEK1/2 (MM cell line)

AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor that binds to the distinctive MEK allosteric site and therefore exhibits exquisite kinase selectivity. AS703026 inhibits growth and survival of human multiple myeloma (MM) cells, including U266 and INA-6, with IC50 of 5 nM and 11 nM, respectively. Such an inhibitory effect by AS703026 is mediated by G0-G1 cell cycle arrest and is accompanied by reduced expresson of the MAF oncogene. AS703026 further induces apoptosis via caspase-3 and PARP cleavage in MM cells, both in the presence or JPence of bone marrow stromal cells (BMSCs). AS703026 may be an effective therapy in colorectal cancer caused by K-Ras mutation. AS703026 (10 μM) effectively inhibits the ERK pathway, proliferation, and transformation in human DLD-1 colorectal cancer cells what carry a mutant allele of K-Ras (D-MUT).

AS703026 (15 and 30 mg/kg) significantly inhibits tumor growth in a human plasmacytoma xenograft model of H929 MM cells. This can be correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels. AS703026 (10 mg/kg) inhibits tumor growth, and markedly decreases p-ERK level in a xenograft mouse model of human K-Ras mutated (D-MUT) colorectal tumor.

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoonet al. Cancer Res. 2011 Jan 15;71(2):445-53. PMID:

分子结构图